Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]

View source ↗

Summary

Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• LOXO-338

Snippet

Sponsor: Eli Lilly and Company | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone | Phase 1 | Status: ACTIVE_NOT_RECRUITING